Abstract：
BACKGROUND: PReferentially expressed Antigen in MElanoma (PRAME) has shown utility in differentiating benign from malignant melanocytic neoplasms. In this study, we investigated the clinical significance of PRAME expression in dysplastic nevi (DN) and nevus-associated melanoma in situ (MIS).
METHODS: We included 172 DN and 38 nevus-associated MIS from our institutional archive. PRAME positive expression was defined as nuclear staining in at least 75% of melanocytes. In addition, relevant studies from PubMed and Web of Science were incorporated into a meta-analysis using the random-effects model to assess PRAME expression in MIS and DN.
RESULTS: Our institutional data revealed that 71.1% of nevus-associated MIS cases exhibited positive PRAME expression in the MIS components, whereas all DN components were negative for PRAME. 5.7% of cases diagnosed as DN in our cohort demonstrated diffuse positivity for PRAME. Notably, MIS associated with DN displaying epidermal and dermal components displayed a higher likelihood of PRAME positivity compared to those arising on a background of DN with solely epidermal (junctional) components (84% vs. 46%, p = 0.024). The meta-analysis indicated that the pooled PRAME positivity in MIS and DN was 54.5% and 1.9%, respectively.
CONCLUSIONS: PRAME is a valuable immunohistochemical marker for differentiating MIS from DN, particularly in the context of nevus-associated MIS.
METHODS: We included 172 DN and 38 nevus-associated MIS from our institutional archive. PRAME positive expression was defined as nuclear staining in at least 75% of melanocytes. In addition, relevant studies from PubMed and Web of Science were incorporated into a meta-analysis using the random-effects model to assess PRAME expression in MIS and DN.
RESULTS: Our institutional data revealed that 71.1% of nevus-associated MIS cases exhibited positive PRAME expression in the MIS components, whereas all DN components were negative for PRAME. 5.7% of cases diagnosed as DN in our cohort demonstrated diffuse positivity for PRAME. Notably, MIS associated with DN displaying epidermal and dermal components displayed a higher likelihood of PRAME positivity compared to those arising on a background of DN with solely epidermal (junctional) components (84% vs. 46%, p = 0.024). The meta-analysis indicated that the pooled PRAME positivity in MIS and DN was 54.5% and 1.9%, respectively.
CONCLUSIONS: PRAME is a valuable immunohistochemical marker for differentiating MIS from DN, particularly in the context of nevus-associated MIS.
摘要：
背景：在MELanoma（PRAME）中优先表达的抗原已显示出区分良性和恶性黑素细胞肿瘤的效用。在这项研究中,我们研究了PRAME在发育不良痣(DN)和痣相关黑色素瘤(MIS)中表达的临床意义.
方法：我们从机构档案中包括了172个DN和38个痣相关的MIS。PRAME阳性表达被定义为在至少75%的黑素细胞中的核染色。此外,使用随机效应模型将PubMed和WebofScience的相关研究纳入meta分析,以评估PRAME在MIS和DN中的表达.
结果：我们的机构数据显示，71.1％的痣相关MIS病例在MIS组件中表现出PRAME阳性表达，而所有DN成分的PRAME均为阴性。在我们的队列中，有5.7％的被诊断为DN的病例表现出PRAME的弥漫性阳性。值得注意的是,与显示表皮和真皮成分的DN相关的MIS与仅具有表皮（连接）成分的DN背景下出现的MIS相比，PRAME阳性的可能性更高（84％vs.46%,p=0.024)。荟萃分析表明，MIS和DN的合并PRAME阳性率分别为54.5％和1.9％，分别。
结论：PRAME是区分MIS和DN的有价值的免疫组织化学标记，特别是在痣相关MIS的背景下。
方法：我们从机构档案中包括了172个DN和38个痣相关的MIS。PRAME阳性表达被定义为在至少75%的黑素细胞中的核染色。此外,使用随机效应模型将PubMed和WebofScience的相关研究纳入meta分析,以评估PRAME在MIS和DN中的表达.
结果：我们的机构数据显示，71.1％的痣相关MIS病例在MIS组件中表现出PRAME阳性表达，而所有DN成分的PRAME均为阴性。在我们的队列中，有5.7％的被诊断为DN的病例表现出PRAME的弥漫性阳性。值得注意的是,与显示表皮和真皮成分的DN相关的MIS与仅具有表皮（连接）成分的DN背景下出现的MIS相比，PRAME阳性的可能性更高（84％vs.46%,p=0.024)。荟萃分析表明，MIS和DN的合并PRAME阳性率分别为54.5％和1.9％，分别。
结论：PRAME是区分MIS和DN的有价值的免疫组织化学标记，特别是在痣相关MIS的背景下。
